The COVID-19 outbreak has left its mark on the work of mental health care staff. Many professionals had to radically change their working conditions or were delegated to work in different facilities, in many cases taking on different responsibilities with little time for training. Many psychiatrists overnight had to partially or fully start working within telemedicine. Due to the lockdown, psychiatric trainees in many countries were not able to complete their training as planned. The measures taken by the governments to limit the impact of the pandemic also affected the capacity to conduct research studies and directions of new research initiatives. During this session the effects of the outbreak on work and wellbeing of early career psychiatrists and researchers in the field of mental health as well as their perspectives in the near future will be discussed.

Routine challenges such as non-response at established daily doses, poor adherence or pharmacokinetic interactions with clinical consequences and adverse effects (pharmacovigilance) comprise a major part of psychopharmacotherapy. Therapeutic drug monitoring and pharmacogenetic tests are valuable tools that allow fort treatment tailoring in routine clinical care. This course will be centered on the following issues: • Introduction: Definition of TDM in psychiatry, theoretical background, practical recommendations; cytochrome P-450: polymorphisms, clinical consequences of a genetic particularity in metabolism, practical recommendations for genotyping and phenotyping. • Presentation of vignettes: TDM alone and in combination with pharmacogenetic tests: general situations; situations of interactions, combination treatments; in special populations (elderly, forensic patients, pregnant patients, adolescents, somatically ill patients); pharmacovigilance